INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51701, 4854, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51702, 4857, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51703, 6172, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51704, 7761, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51705, 7762, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51706, 11246, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51707, 11247, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51708, 11248, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51709, 11589, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51710, 13777, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51711, 13778, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51712, 13792, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51713, 18855, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51714, 18856, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51715, 18862, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51716, 18863, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51717, 18864, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51718, 19024, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51719, 19025, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51720, 19027, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51721, 19029, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51722, 19030, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51723, 21853, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51724, 24263, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51725, 24264, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51726, 25712, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51727, 25713, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51728, 26547, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51729, 26548, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51730, 32786, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51731, 6486, 'Flibanserin', 'Alcoholic Intoxication', 'The use of flibanserin is contraindicated along with the ingestion of alcohol, as it increases the risk of hypotension and syncope.  It is important to assess the likelihood of the patient abstaining from alcohol, taking into account the current and past drinking behavior.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51732, 14290, 'Flibanserin', 'Alcoholic Intoxication', 'The use of flibanserin is contraindicated along with the ingestion of alcohol, as it increases the risk of hypotension and syncope.  It is important to assess the likelihood of the patient abstaining from alcohol, taking into account the current and past drinking behavior.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51733, 19135, 'Flibanserin', 'Alcoholic Intoxication', 'The use of flibanserin is contraindicated along with the ingestion of alcohol, as it increases the risk of hypotension and syncope.  It is important to assess the likelihood of the patient abstaining from alcohol, taking into account the current and past drinking behavior.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51734, 31966, 'Flibanserin', 'Alcoholic Intoxication', 'The use of flibanserin is contraindicated along with the ingestion of alcohol, as it increases the risk of hypotension and syncope.  It is important to assess the likelihood of the patient abstaining from alcohol, taking into account the current and past drinking behavior.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51735, 6486, 'Flibanserin', 'Hypotension', 'The use of flibanserin can cause hypotension and syncope.  The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension.  Flibanserin should be used with caution in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51736, 14290, 'Flibanserin', 'Hypotension', 'The use of flibanserin can cause hypotension and syncope.  The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension.  Flibanserin should be used with caution in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51737, 19135, 'Flibanserin', 'Hypotension', 'The use of flibanserin can cause hypotension and syncope.  The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension.  Flibanserin should be used with caution in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51738, 31966, 'Flibanserin', 'Hypotension', 'The use of flibanserin can cause hypotension and syncope.  The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension.  Flibanserin should be used with caution in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51739, 6486, 'Flibanserin', 'Liver Diseases', 'Flibanserin may accumulate in patients with hepatic impairment.  Therapy with flibanserin is contraindicated in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51740, 14290, 'Flibanserin', 'Liver Diseases', 'Flibanserin may accumulate in patients with hepatic impairment.  Therapy with flibanserin is contraindicated in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51741, 19135, 'Flibanserin', 'Liver Diseases', 'Flibanserin may accumulate in patients with hepatic impairment.  Therapy with flibanserin is contraindicated in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51742, 31966, 'Flibanserin', 'Liver Diseases', 'Flibanserin may accumulate in patients with hepatic impairment.  Therapy with flibanserin is contraindicated in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51743, 0, 'Floxuridine', 'Dihydropyrimidine Dehydrogenase Deficiency', 'An inherited deficiency of dihydropyrimidine can alter the clearance of 5- FU and result in severe toxicity such as stomatitis, diarrhea, neutropenia and neurotoxicity. When administered as a continuous intra-arterial infusion, floxuridine (FUDR) is metabolized to FDUMP.  However, with rapid intra-arterial injection, FUDR is metabolized to 5-FU.  5-FU requires metabolized to an inactive form by dihydropyrimidine dehydrogenase.   FUDR should not be administered by rapid intra-arterial infusion to patients with dihydropyrimidine deficiency.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51744, 0, 'Floxuridine', 'Infections', 'The use of floxuridine (FUDR) is contraindicated in patients with potentially serious infectious diseases.  FUDR can induce myelosuppression.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with FUDR.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51745, 0, 'Floxuridine', 'Malnutrition', 'Floxuridine therapy is contraindicated for patients in a poor nutritional state.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51746, 0, 'Floxuridine', 'Bone Marrow Failure Disorders', 'The use of floxuridine (FUDR) is contraindicated in patients with bone marrow suppression.  FUDR induces myelosuppression at recommended dosages.  Therapy with FUDR should be administered cautiously in patients who have had prior high-dose pelvic irradiation or alkylating agents or who have widespread metastatic tumor involvement of the bone marrow.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended and therapy should be withheld if platelet counts falls below 100,000/mm3 and/or white blood cell (WBC) counts falls below 3500/mm3 or a rapid fall in WBC is noted.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51747, 0, 'Floxuridine', 'Stomatitis', 'Floxuridine induces stomatitis within the gastrointestinal tract.  Therapy with floxuridine should be administered with extreme caution in patients with peptic ulcer disease and ulcerative colitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51748, 0, 'Floxuridine', 'Hemorrhagic Disorders', 'Floxuridine (FUDR) induces myelosuppression.  Therapy with FUDR should be administered cautiously in patients with bleeding tendencies.  Therapy with FUDR should be promptly discontinued following bleeding from any sight.  Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena.   Close clinical monitoring of hematopoietic function is recommended.  Therapy with FUDR should be withheld if platelet counts falls below 100,000/mm3.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51749, 0, 'Flunisolide', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51750, 0, 'Flunisolide', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51751, 0, 'Flunisolide', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51752, 0, 'Flunisolide', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51753, 0, 'Flunisolide', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51754, 347, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51755, 682, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51756, 785, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51757, 1992, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51758, 3542, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51759, 3663, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51760, 3664, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51761, 3665, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51762, 3666, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51763, 3667, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51764, 4360, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51765, 4960, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51766, 4993, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51767, 4994, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51768, 5203, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51769, 8612, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51770, 11598, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51771, 12546, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51772, 13070, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51773, 13446, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51774, 13531, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51775, 14067, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51776, 14150, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51777, 14151, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51778, 14152, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51779, 15757, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51780, 17257, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51781, 17642, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51782, 19147, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51783, 19201, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51784, 19202, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51785, 19208, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51786, 21162, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51787, 23321, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51788, 23322, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51789, 23323, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51790, 23324, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51791, 27679, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51792, 28496, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51793, 28497, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51794, 28730, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51795, 31820, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51796, 32275, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51797, 33255, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51798, 347, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51799, 682, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51800, 785, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '', 'DDInter', 0);
